Indegene Inc: Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
Go-to-Market Solution Provides Full Commercial Support for the First, True Entire Active-Day Medication Designed to treat ADHD Indegene Model Geared for Efficient National Commercial Launch in Multibillion-Dollar
Source: finanznachrichten.de